Recent clinical trials of surfactant treatment for neonates

Biology of the Neonate

Volumn 89, Issue 4, 2006, Pages 323-329

  Halliday, Henry L ^a,b  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Clinical trials; Meconium aspiration syndrome; Neonate; Respiratory distress syndrome; Surfactants; Systematic reviews

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL LUNG SURFACTANT; BERACTANT; BLES; BOVACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; NEWFACTAN; NEWFACTANT; PORACTANT; PUMACTANT; RESPIRATORY TRACT AGENT; STEROID; SURFACEN; SURFACTANT TA; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED PRACTICE; EXTRACORPOREAL OXYGENATION; HUMAN; INTERVENTION STUDY; LUNG HEMORRHAGE; MECONIUM ASPIRATION; META ANALYSIS; NEWBORN DISEASE; POPULATION RESEARCH; POPULATION SIZE; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZATION; RESPIRATORY DISTRESS SYNDROME; STEROID THERAPY; SYSTEMATIC REVIEW;

CLINICAL TRIALS; HUMANS; INFANT, NEWBORN; MECONIUM ASPIRATION SYNDROME; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURFACE-ACTIVE AGENTS;

ANIMALIA;

EID: 33745113132     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092869     Document Type: Conference Paper

References (40)

1. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T: Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;i:55-59.
2. Halliday HL: History of surfactant from 1980. Biol Neonate 2005;87:317-322.
3. Jobe AH: Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868.
4. Soll RF, Dargaville P: Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev 2000;2:CD002054.
5. Bloom BT, Clark RH; Infasurf Survanta Clinical trial Group. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005;116:392-399.
6. Malloy CA, Nicoski P, Muraskas JK: A randomised trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005;94:779-784.
7. Sanchez-Mendiola M, Martinez-Natera OC, Herrera-Maldonado N, Ortega-Arroyo J: Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant: a controlled study. Gac Med Mex 2005;141:267-271.
8. Choi CW, Hwang JH, Yoo EJ, Kim KA, Koh SY, Lee YK, Shim JW, Lee EK, Chang W, Kim SS, Chang YS, Park WS, Shin SM: Comparison of clinical efficacy of Newfactan versus Surfacten for the treatment of respiratory distress syndrome in the newborn infants. J Korean Med Sci 2005;20:591-597.
9. Sinha SK, Lacaze-Masmonteil T, Valls-I-Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agnostino R; Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005;115:1030-1038.
10. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R; International Surfaxin Collaborative Group: a multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005;115:1018-1029.
11. Lam BC, Ng YK, Wong KY: Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome. Pediatr Pulmonol 2005;39:64-69.
12. Yalaz M, Arslanoglu S, Akisu M, Atik T, Ergun O, Kultursay N: A comparison of efficacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. Klin Pädiatr 2004;216:230-235.
13. Hammoud M, Al-Kazmi N, Alshemmiri M, Thalib L, Ranjani VT, Devarajan LV, Elsori H: Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome. J Matem Fetal Neonatal Med 2004;15:167-175.
14. Attar MA, Becker MA, Dechert RE, Donn SM: Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol 2004;24:626-630.
15. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group: A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21:109-119.
16. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C: Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003;162:476-480.
17. Beresford MW, Shaw NJ: Bronchoalveolar lavage surfactant protein A, B, and D concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatr Res 2003;53:663-670.
18. Giannakopoulou C, Hatzidaki E, Korakaki E, Christodoulaki M, Margari KM, Mamoulakis D: Comparative randomized study: administration of natural and synthetic surfactant to premature newborns with respiratory distress syndrome. Pediatr Int 2002;44:117-121.
19. Murdoch E, Kempley ST: The effects of synthetic and natural surfactant on fluid balance in acute respiratory distress syndrome. Eur J Pediatr 2000;159:767-769.
20. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V: Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant? Acta Paediatr 2000;89:556-561.
21. Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, Ward Platt MP: Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet 2000;355:1387-1392.
22. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Keszler M, Visser VE, Merritt TA, Mannino FL, Mastrioianni L, Marcy B, Revak SD, Tsai H, Cochrane CG: A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002;109:1081-1087.
23. Chinese Collaborative Study Group for Neonatal Respiratory Diseases: Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr 2005;94:896-902.
24. Kattwinkel J: Surfactant lavage for meconium aspiration: a word of caution. Pediatrics 2002;109:1167-1168.
25. Soll RF, Morley CJ: Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000;2:CD000510.
26. Soll RF, Blanco F: Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2001;2:CD000144.
27. Sinn JKH, Ward MC, Henderson-Smart DJ: Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health 2002;38:597-600.
28. Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE: Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004;24:360-365.
29. Trevisanuto D, Grazzina N, Ferrarese P, Micaglio M, Verghese C, Zanardo V: Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 2005;87:217-220.
30. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, Schollin J: Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000;89:460-464.
31. Horbar JD, Carpenter JH, Buzas J, Soil RF, Suresh G, Bracken MB, Leviton LC, Plsek PE, Sinclair JC for the members of the Vermont Oxford Network: Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based? Pediatrics 2004;113:1593-1602.
32. Horbar JD, Carpenter JH, Buzas J, Soil RF, Suresh G, Bracken MB, Leviton LC, Plsek PE, Sinclair JC: Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. BMJ 2004;329:1004-1007.
33. Walti H, Paris-Llado J, Egberts J, Brand R, Bevilacqua G, Gardini F, Breart G: Prophylactic administration of porcine-derived lung surfactant is a significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants. Biol Neonate 2002;81:182-187.
34. Hintz SR, Poole WK, Wright LL, Fanaroff AA, Kendrick DE, Laptook AR, Goldberg R, Duara S, Stoll BJ, Oh W for the NICHD Neonatal Research Network: Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era. Arch Dis Child Fetal Neonatal Ed 2005;90:F128-F133.
35. Clarkson A, Choonara I: Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002;87:462-467.
36. Obladen M: History of surfactant before 1980. Biol Neonate 2005;87:308-316.
37. Halliday HL: Natural vs. synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51:226-237
38. Fox GF, Sothinathan U: The choice of surfactant for treatment of respiratory distress syndrome in preterm infants: a review of the evidence. Infant 2005;1:8-12.
39. Kattwinkel J: Synthetic surfactants: the search goes on. Pediatrics 2005;115:1075-1076.
40. Raju T, Langenberg P: Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr 1993;123:603-610.